Lexaria Bioscience Corp (LEXX)

[Shawking]

Update from Chris Bunka

Hypertension study Hyper-H21-4- "Hypertension results are a bit slow in coming from the clinicians in part due to the sheer volume of work. But it is starting to arrive (finally) and we should have initial results to report in the next two weeks or maybe even less."

Epilepsy research EPIL-A21-1 - "Epilepsy study is ongoing. It turns out that it is a really complex series of studies. and earlier in the summer we had to re-calibrate certain things that cost us nearly two months. That said, we are nearing the end of the first "half" and expect to have results from that portion in November."

Human nicotine study NIC-H22-1- "We've been waiting for some time for IRB approval on the nicotine study - that's an independent entity and they told us originally they would need 7-10 days: instead we have been waiting over a month. Should be achieved "soon".